Results 1 to 10 of about 37,305 (235)

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma [PDF]

Blood Advances, 2018
: There is an unmet need for effective biological therapies for relapsed central nervous system (CNS) lymphoma. Lenalidomide is active in activated B-cell type diffuse large B-cell lymphoma and rituximab is effective in CNS lymphoma.
James L. Rubenstein, Huimin Geng, Eleanor J. Fraser, Paul Formaker, Lingjing Chen, Jigyasa Sharma, Phoebe Killea, Kaylee Choi, Jenny Ventura, John Kurhanewicz, Clifford Lowell, Jimmy Hwang, Patrick Treseler, Penny K. Sneed, Jing Li, Xiaomin Wang, Nianhang Chen, Jon Gangoiti, Pamela N. Munster, Bertil Damato   +19 more
doaj   +2 more sources

Original Versus Generic Lenalidomide in Patients with Relapsed/ Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events

Turkish Journal of Hematology, 2021
Objective: Lenalidomide is an effective immunomodulatory derivative drug used in the treatment of multiple myeloma (MM). It is available in original and generic forms in Turkey, but there is no clinical study that has compared the effectiveness and ...
Ali Zahit Bolaman, Atakan Turgutkaya, Birsen Sahip, Cem Selim, Ayşe Hilal Eroğlu Küçükdiler, Şehmus Ertop, Gökhan Sargın, İrfan Yavaşoğlu   +7 more
doaj   +1 more source

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Haematologica, 2020
n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma.
Sara Bringhen, Mattia D’Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota-Scalabrini, Luca De Rosa, Vincenzo Pavone, Giulia Gazzera, Sara Aquino, Marco Poggiu, Armando Santoro, Massimo Gentile, Luca Baldini, Maria Teresa Petrucci, Patrizia Tosi, Roberto Marasca, Claudia Cellini, Antonio Palumbo, Patrizia Falco, Roman Hájek, Mario Boccadoro, Alessandra Larocca   +25 more
doaj   +1 more source

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

Life, 2023
This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) improve clinical outcomes in patients with myeloma; however, refractoriness to ...
Kazuhito Suzuki, Shingo Yano
doaj   +1 more source

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context

EClinicalMedicine, 2023
Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome.
John R. Jones, David A. Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Molly Reed, Mark T. Drayson, Roger G. Owen, Kevin D. Boyd, Gordon Cook, Gareth J. Morgan, Graham H. Jackson   +16 more
doaj   +1 more source

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Blood Advances, 2019
: To gain insights into the characteristics of clinical resistance to lenalidomide, we evaluated the outcomes of 147 consecutive patients with multiple myeloma (MM) homogeneously treated with immunomodulatory imide drugs (IMiDs) pomalidomide and ...
Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios C. Ziogas, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Ioanna Dialoupi, Stavroula Giannouli, Panagiotis Tsirigotis, Sossana Delimpasi, Despina Mparmparousi, Mairylin Spyropoulou-Vlachou, Aikaterini Xirokosta, Evangelos Terpos, Meletios A. Dimopoulos   +17 more
doaj   +1 more source

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. [PDF]

PLoS Medicine, 2008
Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia.
Benjamin L Ebert, Naomi Galili, Pablo Tamayo, Jocelyn Bosco, Raymond Mak, Jennifer Pretz, Shyam Tanguturi, Christine Ladd-Acosta, Richard Stone, Todd R Golub, Azra Raza   +10 more
doaj   +1 more source

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

Frontiers in Oncology, 2021
BackgroundThe treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway.
Catherine S. Y. Lecat, Catherine S. Y. Lecat, Jessica B. Taube, William Wilson, Jonathan Carmichael, Jonathan Carmichael, Christopher Parrish, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Neil K. Rabin, Jonathan Sive, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Gordon Cook, Rakesh Popat   +18 more
doaj   +1 more source

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

Mediterranean Journal of Hematology and Infectious Diseases, 2021
Considerable data indicate posttransplant lenalidomide prolongs progression-free survival and probably survival after an autotransplant for plasma cell myeloma (PCM).
Monia Marchetti , Robert Peter Gale, Giovanni Barosi   +2 more
doaj   +3 more sources

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma

Hematology Reports, 2012
Novel agents such as lenalidomide have demonstrated responses similar to high-dose melphalan and autologous stem cell transplant in multiple myeloma.
Rishi Agarwal, Muneer H. Abidi
doaj   +1 more source